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Infectious complications following cardiac surgery are asso-
ciated with increased mortality, prolonged hospital stay and
increased health care costs [1]. The prevalence of post-cardiac
surgery infections ranges between 5 and 21 %, depend-
ing on whether surgical site (sternal wound and leg
harvest site infections) or non-surgical site infections
(pneumonia, urinary tract infection, bacteraemia, Clos-
tridium colitis) are taken into account [2]. The incidence
of post-cardiac surgery infections is expected to increase
with an ageing population and the increased use of
cardiac surgery in higher risk groups, such as diabetics,
obese patients, and patients undergoing repeat surgery.
Consequently, early identification of high-risk patients
and implementing risk-reducing interventions are be-
coming increasingly important.
Statins are frequently prescribed drugs with widely
accepted cardiovascular benefits. Beyond cholesterol lower-
ing, they are also recognised for their anti-inflammatory and
immune-modulating properties. Because of these so-called
pleiotropic effects, statins may be beneficial for the prevention
of post-cardiac surgery infectious complications. In this issue
of the journal, Hartholt et al. report in a retrospective
cohort analysis of 520 patients undergoing cardiothorac-
ic surgery (coronary artery bypass grafting [CABG],
valve surgery, aortic surgery, or other), that preoperative
statin therapy was associated with a 67 % reduced risk
of postoperative infections (adjusted odds ratio 0.33.
95 % CI 0.19–0.57, p<0.001) [3]. Overall, postopera-
tive infections occurred in 15.8 % of patients (12.2 %
in statin group and 24.7 % in control group, p=0.001).
The association of preoperative statin therapy with
reduced postoperative infections exclusively concerned
non-surgical site but not surgical site infections. In
addition, reduced in-hospital mortality was found in
preoperative statin users (3.2 % versus 7.3 %, P=
0.041).
At first glance, these results appear promising but they
should be placed in a broader perspective. Results of previous
observational studies and meta-analyses evaluating the asso-
ciation of preoperative statin therapy and post-cardiac surgery
infections have been mixed and conflicting, as the authors
acknowledge [4–7]. Compared with previous ‘positive asso-
ciation’ studies, the current study by Hartholt et al. shows
remarkable and difficult to explain differences. Although a
small cohort study compared with others (520 versus 1934
and 6253 patients), postoperative infections occurred twice as
often (15.8 % versus 7.2 % and 7.8 %), while the observed
risk reduction was largest (67 % versus 26% and 33%) [6, 7].
In the study by Kayani et al., preoperative statin therapy was
associated with an overall reduction of post-cardiac surgery
infections, and mainly concerned a reduction of surgical site
infections but not pneumonia and sepsis. This is in contrast
with the study by Hartholt et al., who report a reduction in
pneumonia and urinary tract infections instead. These diver-
gent results can be explained by methodological deficiencies
of observational studies in general. Observational studies
demonstrate associations rather than causal relationships and
despite the availability of accurate statistical adjustment there
is always the risk of unmeasured confounding. Some of these
confounding variables include 1) the prescription of
statins to patients with high cholesterol, which is in
itself associated with a lower risk of infection, and 2)
the positive selection of ‘healthier’ patients because of
their better tolerance to statins (less healthy patients will
be less likely to take statins). Randomised placebo-
controlled clinical trials investigating the true effect of
preoperative statin therapy and post-cardiac surgery
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infections are currently lacking. A recent meta-analysis
investigated data from 11 randomised placebo-controlled
statin trials (30,947 patients, 45.6 % receiving statins)
that were designed to mainly investigate cardiovascular
events, but reported infectious complications as well.
Interestingly, the meta-analysis did not find evidence
for a reduced risk of infections and infection-related
mortality in patients taking statins (relative risk 1.00
(95 % CI 0.96–1.05) and 0.97 (95 % CI 0.83–1.13),
respectively) [8].
The mechanism by which statins could exert their
infection-reducing effects remains speculative. Although
statins have anti-inflammatory and immune-modulating
effects, they have no direct antibacterial effects and are
by no means antibiotics. In vitro studies of the anti-
inflammatory effects of statins are misleading, because
the minimum inhibitory concentrations needed far ex-
ceed pharmacological levels that can be achieved with
usual human doses [9]. Furthermore, if statins really
reduce the risk of postoperative infections, why do they
exert this protective effect mainly when prescribed pre-
operatively? Indeed, Hartholt et al. showed that postop-
erative initiation of statin therapy (in 7.1 % of patients)
was not associated with a reduced risk of infection.
For sure, Hartholt et al. are complimented on their positive
findings but their study adds to a list of existing observational
studies and does not give us the definitive answer whether
statins truly reduce postoperative infections. Although large
randomised clinical trials could help to solve this problem, it is
questionable whether these are doable. Because many patients
undergoing cardiac surgery (especially CABG) have a class I
indication for statins and stopping statins would be unethical,
the study would have to be limited to patients without coro-
nary artery disease undergoing valve surgery only [10]. Fur-
thermore, designing such a randomised clinical trial is com-
plicated because the type, dose and time point when to start
statin before surgery are currently unknown. For now, there is
still insufficient evidence that statins reduce infections.
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